25 XP   0   0   10

Laboratorios Farmaceuticos ROVI
Buy, Hold or Sell?

Let's analyse Rovi together

PenkeI guess you are interested in Laboratorios Farmaceuticos ROVI. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Laboratorios Farmaceuticos ROVI. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Laboratorios Farmaceuticos ROVI

I send you an email if I find something interesting about Laboratorios Farmaceuticos ROVI.

Quick analysis of Rovi (30 sec.)










What can you expect buying and holding a share of Rovi? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨1.40
When do you have the money?
1 year
How often do you get paid?
82.5%

What is your share worth?

Current worth
‚ā¨10.21
Expected worth in 1 year
‚ā¨9.76
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨0.85
Return On Investment
0.9%

For what price can you sell your share?

Current Price per Share
‚ā¨89.15
Expected price per share
‚ā¨84.65 - ‚ā¨94.80
How sure are you?
50%

1. Valuation of Rovi (5 min.)




Live pricePrice per Share (EOD)

‚ā¨89.15

Intrinsic Value Per Share

‚ā¨-6.78 - ‚ā¨21.98

Total Value Per Share

‚ā¨3.43 - ‚ā¨32.19

2. Growth of Rovi (5 min.)




Is Rovi growing?

Current yearPrevious yearGrowGrow %
How rich?$563.9m$520.5m$55.9m9.7%

How much money is Rovi making?

Current yearPrevious yearGrowGrow %
Making money$37.1m$52.2m-$15.1m-40.8%
Net Profit Margin16.7%23.1%--

How much money comes from the company's main activities?

3. Financial Health of Rovi (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#103 / 994

Most Revenue
#48 / 994

Most Profit
#38 / 994

What can you expect buying and holding a share of Rovi? (5 min.)

Welcome investor! Rovi's management wants to use your money to grow the business. In return you get a share of Rovi.

What can you expect buying and holding a share of Rovi?

First you should know what it really means to hold a share of Rovi. And how you can make/lose money.

Speculation

The Price per Share of Rovi is ‚ā¨89.15. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rovi.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rovi, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨10.21. Based on the TTM, the Book Value Change Per Share is ‚ā¨-0.11 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨0.69 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.32 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rovi.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps0.310.4%0.951.1%1.181.3%0.720.8%0.420.5%
Usd Book Value Change Per Share-0.30-0.3%-0.12-0.1%0.740.8%0.260.3%0.200.2%
Usd Dividend Per Share0.000.0%0.350.4%1.111.3%0.450.5%0.280.3%
Usd Total Gains Per Share-0.30-0.3%0.230.3%1.862.1%0.720.8%0.480.5%
Usd Price Per Share87.11-63.20-47.68-48.32-31.93-
Price to Earnings Ratio69.37-26.53-14.49-23.44-61.51-
Price-to-Total Gains Ratio-287.93-79.34-45.03-105.86-110.87-
Price to Book Ratio7.93-5.74-5.14-5.57-4.79-
Price-to-Total Gains Ratio-287.93-79.34-45.03-105.86-110.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share95.987805
Number of shares10
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.350.45
Usd Book Value Change Per Share-0.120.26
Usd Total Gains Per Share0.230.72
Gains per Quarter (10 shares)2.287.16
Gains per Year (10 shares)9.1128.66
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
114-5-1181119
228-108362148
342-1517543277
456-19267342106
570-24359153135
684-294410963164
798-345312774193
8112-396214584222
9126-447116395251
10140-4880181105280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%65.01.01.097.0%
Book Value Change Per Share2.02.00.050.0%8.04.00.066.7%16.04.00.080.0%34.06.00.085.0%53.07.07.079.1%
Dividend per Share3.00.01.075.0%11.00.01.091.7%18.00.02.090.0%33.00.07.082.5%47.00.020.070.1%
Total Gains per Share2.02.00.050.0%10.02.00.083.3%18.02.00.090.0%36.04.00.090.0%58.05.04.086.6%

Fundamentals of Rovi

About Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmace√ļticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Fundamental data was last updated by Penke on 2024-06-10 02:58:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Laboratorios Farmaceuticos ROVI.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Rovi earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Rovi to the¬†Biotechnology industry mean.
  • A Net Profit Margin of 9.9%¬†means that¬†€0.10 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 9.9%. The company is making a profit. +1
  • The TTM is 16.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ9.9%TTM16.7%-6.8%
TTM16.7%YOY23.1%-6.4%
TTM16.7%5Y18.5%-1.7%
5Y18.5%10Y13.2%+5.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.9%-178.5%+188.4%
TTM16.7%-223.7%+240.4%
YOY23.1%-245.1%+268.2%
5Y18.5%-390.8%+409.3%
10Y13.2%-503.2%+516.4%
1.1.2. Return on Assets

Shows how efficient Rovi is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Rovi to the¬†Biotechnology industry mean.
  • 1.9% Return on Assets means that¬†Rovi generated¬†€0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 1.9%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.9%TTM4.2%-2.3%
TTM4.2%YOY5.8%-1.6%
TTM4.2%5Y4.4%-0.2%
5Y4.4%10Y3.1%+1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9%-11.6%+13.5%
TTM4.2%-11.6%+15.8%
YOY5.8%-10.9%+16.7%
5Y4.4%-12.9%+17.3%
10Y3.1%-14.1%+17.2%
1.1.3. Return on Equity

Shows how efficient Rovi is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Rovi to the¬†Biotechnology industry mean.
  • 2.9% Return on Equity means Rovi generated €0.03¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 2.9%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 6.4%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.9%TTM6.4%-3.5%
TTM6.4%YOY9.9%-3.5%
TTM6.4%5Y7.0%-0.6%
5Y7.0%10Y5.0%+2.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9%-14.0%+16.9%
TTM6.4%-14.9%+21.3%
YOY9.9%-13.5%+23.4%
5Y7.0%-18.2%+25.2%
10Y5.0%-19.0%+24.0%

1.2. Operating Efficiency of Laboratorios Farmaceuticos ROVI.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Rovi is operating .

  • Measures how much profit Rovi makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Rovi to the¬†Biotechnology industry mean.
  • An Operating Margin of 12.7%¬†means the company generated €0.13 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 12.7%. The company is operating less efficient.
  • The TTM is 21.8%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ12.7%TTM21.8%-9.0%
TTM21.8%YOY29.6%-7.8%
TTM21.8%5Y22.9%-1.1%
5Y22.9%10Y15.8%+7.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.7%-344.0%+356.7%
TTM21.8%-235.7%+257.5%
YOY29.6%-262.3%+291.9%
5Y22.9%-383.7%+406.6%
10Y15.8%-485.1%+500.9%
1.2.2. Operating Ratio

Measures how efficient Rovi is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Biotechnology industry mean).
  • An Operation Ratio of 0.87 means that the operating costs are €0.87 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.872. The company is less efficient in keeping operating costs low.
  • The TTM is 0.783. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.872TTM0.783+0.089
TTM0.783YOY0.704+0.079
TTM0.7835Y0.771+0.012
5Y0.77110Y0.842-0.071
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8723.092-2.220
TTM0.7833.353-2.570
YOY0.7043.564-2.860
5Y0.7714.836-4.065
10Y0.8426.187-5.345

1.3. Liquidity of Laboratorios Farmaceuticos ROVI.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Rovi is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Biotechnology industry mean).
  • A Current Ratio of 2.54¬†means the company has €2.54 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 2.538. The company is able to pay all its short-term debts. +1
  • The TTM is 2.410. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.538TTM2.410+0.128
TTM2.410YOY2.116+0.293
TTM2.4105Y2.629-0.219
5Y2.62910Y2.601+0.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5383.776-1.238
TTM2.4104.034-1.624
YOY2.1164.978-2.862
5Y2.6295.984-3.355
10Y2.6016.360-3.759
1.3.2. Quick Ratio

Measures if Rovi is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Rovi to the¬†Biotechnology industry mean.
  • A Quick Ratio of 0.76¬†means the company can pay off €0.76 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.756. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.841. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.756TTM0.841-0.086
TTM0.841YOY1.015-0.173
TTM0.8415Y1.142-0.300
5Y1.14210Y1.300-0.158
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7563.198-2.442
TTM0.8413.631-2.790
YOY1.0154.843-3.828
5Y1.1425.825-4.683
10Y1.3006.378-5.078

1.4. Solvency of Laboratorios Farmaceuticos ROVI.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Rovi assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Rovi to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.33¬†means that Rovi assets are¬†financed with 32.7% credit (debt) and the remaining percentage (100% - 32.7%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.327. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.351. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.327TTM0.351-0.023
TTM0.351YOY0.421-0.070
TTM0.3515Y0.366-0.016
5Y0.36610Y0.364+0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3270.336-0.009
TTM0.3510.346+0.005
YOY0.4210.284+0.137
5Y0.3660.367-0.001
10Y0.3640.376-0.012
1.4.2. Debt to Equity Ratio

Measures if Rovi is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Rovi to the¬†Biotechnology industry mean.
  • A Debt to Equity ratio of 49.0% means that company has €0.49 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.490. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.551. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.490TTM0.551-0.060
TTM0.551YOY0.743-0.192
TTM0.5515Y0.588-0.038
5Y0.58810Y0.579+0.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4900.383+0.107
TTM0.5510.421+0.130
YOY0.7430.371+0.372
5Y0.5880.447+0.141
10Y0.5790.476+0.103

2. Market Valuation of Laboratorios Farmaceuticos ROVI

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Rovi generates.

  • Above 15 is considered overpriced but¬†always compare¬†Rovi to the¬†Biotechnology industry mean.
  • A PE ratio of 69.37 means the investor is paying €69.37¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The EOD is 76.445. Based on the earnings, the company is expensive. -2
  • The MRQ is 69.371. Based on the earnings, the company is expensive. -2
  • The TTM is 26.530. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD76.445MRQ69.371+7.074
MRQ69.371TTM26.530+42.841
TTM26.530YOY14.494+12.035
TTM26.5305Y23.441+3.088
5Y23.44110Y61.512-38.070
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD76.445-2.430+78.875
MRQ69.371-2.865+72.236
TTM26.530-2.837+29.367
YOY14.494-3.469+17.963
5Y23.441-6.135+29.576
10Y61.512-6.468+67.980
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The EOD is 174.530. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 158.378. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 35.967. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD174.530MRQ158.378+16.151
MRQ158.378TTM35.967+122.411
TTM35.967YOY-5.257+41.224
TTM35.9675Y-6.552+42.519
5Y-6.55210Y24.488-31.040
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD174.530-3.057+177.587
MRQ158.378-3.525+161.903
TTM35.967-3.610+39.577
YOY-5.257-4.805-0.452
5Y-6.552-7.882+1.330
10Y24.488-8.461+32.949
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Rovi is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Biotechnology industry mean).
  • A PB ratio of 7.93 means the investor is paying €7.93¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The EOD is 8.734. Based on the equity, the company is overpriced. -1
  • The MRQ is 7.926. Based on the equity, the company is overpriced. -1
  • The TTM is 5.739. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD8.734MRQ7.926+0.808
MRQ7.926TTM5.739+2.187
TTM5.739YOY5.135+0.603
TTM5.7395Y5.569+0.169
5Y5.56910Y4.791+0.778
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.7341.966+6.768
MRQ7.9262.194+5.732
TTM5.7392.227+3.512
YOY5.1352.447+2.688
5Y5.5693.726+1.843
10Y4.7914.199+0.592
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Laboratorios Farmaceuticos ROVI compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.281-0.113-60%0.690-141%0.245-215%0.182-254%
Book Value Per Share--10.20710.207+0%9.019+13%7.956+28%5.782+77%
Current Ratio--2.5382.410+5%2.116+20%2.629-3%2.601-2%
Debt To Asset Ratio--0.3270.351-7%0.421-22%0.366-11%0.364-10%
Debt To Equity Ratio--0.4900.551-11%0.743-34%0.588-17%0.579-15%
Dividend Per Share---0.324-100%1.035-100%0.421-100%0.263-100%
Eps--0.2920.878-67%1.097-73%0.669-56%0.386-24%
Free Cash Flow Per Share--0.1280.217-41%0.484-74%0.313-59%0.158-19%
Free Cash Flow To Equity Per Share---0.235-0.622+164%0.213-211%-0.054-77%-0.009-96%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--21.984--------
Intrinsic Value_10Y_min---6.778--------
Intrinsic Value_1Y_max--2.118--------
Intrinsic Value_1Y_min--0.413--------
Intrinsic Value_3Y_max--6.429--------
Intrinsic Value_3Y_min--0.303--------
Intrinsic Value_5Y_max--10.818--------
Intrinsic Value_5Y_min---0.836--------
Market Cap4559977925.000+9%4151415293.7003067799029.778+35%2377358334.405+75%2419068320.012+72%1585640409.453+162%
Net Profit Margin--0.0990.167-41%0.231-57%0.185-46%0.132-25%
Operating Margin--0.1270.218-42%0.296-57%0.229-44%0.158-20%
Operating Ratio--0.8720.783+11%0.704+24%0.771+13%0.842+4%
Pb Ratio8.734+9%7.9265.739+38%5.135+54%5.569+42%4.791+65%
Pe Ratio76.445+9%69.37126.530+161%14.494+379%23.441+196%61.512+13%
Price Per Share89.150+9%80.90058.698+38%44.285+83%44.877+80%29.651+173%
Price To Free Cash Flow Ratio174.530+9%158.37835.967+340%-5.257+103%-6.552+104%24.488+547%
Price To Total Gains Ratio-317.293-10%-287.93179.343-463%45.029-739%105.863-372%110.873-360%
Quick Ratio--0.7560.841-10%1.015-26%1.142-34%1.300-42%
Return On Assets--0.0190.042-54%0.058-67%0.044-56%0.031-38%
Return On Equity--0.0290.064-55%0.099-71%0.070-59%0.050-42%
Total Gains Per Share---0.2810.212-233%1.726-116%0.665-142%0.445-163%
Usd Book Value--563956079.400576491828.325-2%520533037.575+8%462638286.390+22%332676128.085+70%
Usd Book Value Change Per Share---0.303-0.121-60%0.743-141%0.263-215%0.196-254%
Usd Book Value Per Share--10.99010.990+0%9.711+13%8.566+28%6.225+77%
Usd Dividend Per Share---0.349-100%1.115-100%0.453-100%0.283-100%
Usd Eps--0.3140.945-67%1.182-73%0.720-56%0.415-24%
Usd Free Cash Flow--7055615.10012117450.975-42%27943595.100-75%18084953.055-61%9076904.010-22%
Usd Free Cash Flow Per Share--0.1370.233-41%0.521-74%0.337-59%0.171-19%
Usd Free Cash Flow To Equity Per Share---0.253-0.670+164%0.229-211%-0.058-77%-0.010-96%
Usd Market Cap4909728231.848+9%4469828846.7273303099215.361+35%2559701718.654+75%2604610860.156+72%1707259028.858+162%
Usd Price Per Share95.988+9%87.10563.200+38%47.682+83%48.319+80%31.926+173%
Usd Profit--16108508.70037102274.475-57%52241484.000-69%33995456.625-53%19854132.660-19%
Usd Revenue--162770122.500209701860.450-22%219040617.900-26%170451246.465-5%121634341.403+34%
Usd Total Gains Per Share---0.3030.228-233%1.858-116%0.716-142%0.479-163%
 EOD+3 -5MRQTTM+10 -25YOY+9 -265Y+8 -2710Y+9 -26

3.2. Fundamental Score

Let's check the fundamental score of Laboratorios Farmaceuticos ROVI based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1576.445
Price to Book Ratio (EOD)Between0-18.734
Net Profit Margin (MRQ)Greater than00.099
Operating Margin (MRQ)Greater than00.127
Quick Ratio (MRQ)Greater than10.756
Current Ratio (MRQ)Greater than12.538
Debt to Asset Ratio (MRQ)Less than10.327
Debt to Equity Ratio (MRQ)Less than10.490
Return on Equity (MRQ)Greater than0.150.029
Return on Assets (MRQ)Greater than0.050.019
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Laboratorios Farmaceuticos ROVI based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.810
Ma 20Greater thanMa 5088.415
Ma 50Greater thanMa 10084.545
Ma 100Greater thanMa 20077.858
OpenGreater thanClose89.300
Total5/5 (100.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets778,663
Total Liabilities254,881
Total Stockholder Equity519,677
 As reported
Total Liabilities 254,881
Total Stockholder Equity+ 519,677
Total Assets = 778,663

Assets

Total Assets778,663
Total Current Assets485,415
Long-term Assets293,248
Total Current Assets
Cash And Cash Equivalents 13,085
Net Receivables 131,488
Inventory 337,971
Total Current Assets  (as reported)485,415
Total Current Assets  (calculated)482,544
+/- 2,871
Long-term Assets
Property Plant Equipment 256,616
Long-term Assets Other 901
Long-term Assets  (as reported)293,248
Long-term Assets  (calculated)257,517
+/- 35,731

Liabilities & Shareholders' Equity

Total Current Liabilities191,246
Long-term Liabilities63,635
Total Stockholder Equity519,677
Total Current Liabilities
Short-term Debt 22,146
Accounts payable 106,639
Other Current Liabilities 62,461
Total Current Liabilities  (as reported)191,246
Total Current Liabilities  (calculated)191,246
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)63,635
Long-term Liabilities  (calculated)0
+/- 63,635
Total Stockholder Equity
Common Stock3,241
Retained Earnings 570,492
Other Stockholders Equity -54,056
Total Stockholder Equity (as reported)519,677
Total Stockholder Equity (calculated)519,677
+/-0
Other
Capital Stock3,241
Cash and Short Term Investments 13,085
Common Stock Shares Outstanding 51,315
Liabilities and Stockholders Equity 778,663
Net Debt 68,689
Net Invested Capital 519,677
Net Working Capital 294,169
Short Long Term Debt Total 81,774



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-03-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
48,602
80,977
89,606
103,480
0
115,736
112,159
115,884
115,884
135,905
135,905
145,403
145,403
164,787
164,787
0
208,259
0
212,887
216,512
217,912
218,307
228,068
219,266
219,267
216,920
222,363
224,992
229,376
236,089
235,923
236,591
247,640
245,329
261,320
261,880
264,596
262,089
263,847
265,401
278,595
271,324
287,848
301,942
303,004
289,626
298,382
307,319
312,247
316,158
402,700
427,665
449,121
452,174
511,211
526,660
543,830
561,714
574,439
591,382
644,245
685,066
732,676
744,859
791,565
772,466
878,703
885,195
899,832
830,725
799,884
778,663
778,663799,884830,725899,832885,195878,703772,466791,565744,859732,676685,066644,245591,382574,439561,714543,830526,660511,211452,174449,121427,665402,700316,158312,247307,319298,382289,626303,004301,942287,848271,324278,595265,401263,847262,089264,596261,880261,320245,329247,640236,591235,923236,089229,376224,992222,363216,920219,267219,266228,068218,307217,912216,512212,8870208,2590164,787164,787145,403145,403135,905135,905115,884115,884112,159115,7360103,48089,60680,97748,602
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
161,931
165,517
164,937
164,723
169,177
160,986
145,350
132,111
131,042
134,195
142,570
144,450
137,483
138,296
155,846
149,623
162,033
163,444
160,748
157,348
154,083
153,884
166,861
158,888
167,072
181,116
182,894
168,446
168,167
177,017
181,573
183,881
254,004
245,528
266,864
269,537
317,885
334,895
351,465
366,856
364,578
386,142
439,297
476,502
506,362
521,958
566,934
543,620
623,073
631,586
637,965
567,063
509,331
485,415
485,415509,331567,063637,965631,586623,073543,620566,934521,958506,362476,502439,297386,142364,578366,856351,465334,895317,885269,537266,864245,528254,004183,881181,573177,017168,167168,446182,894181,116167,072158,888166,861153,884154,083157,348160,748163,444162,033149,623155,846138,296137,483144,450142,570134,195131,042132,111145,350160,986169,177164,723164,937165,517161,931000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
58,635
38,673
52,593
58,934
49,491
37,519
36,489
21,623
16,585
22,193
22,361
17,065
19,401
12,866
25,219
28,241
26,671
27,855
25,673
25,576
29,251
39,930
44,612
40,721
41,378
47,662
54,122
44,171
40,700
38,965
29,966
17,474
95,511
71,308
66,680
42,525
67,426
55,938
35,428
35,283
53,162
72,617
126,746
143,961
99,035
101,736
157,627
97,639
124,945
141,462
153,812
56,377
25,322
13,085
13,08525,32256,377153,812141,462124,94597,639157,627101,73699,035143,961126,74672,61753,16235,28335,42855,93867,42642,52566,68071,30895,51117,47429,96638,96540,70044,17154,12247,66241,37840,72144,61239,93029,25125,57625,67327,85526,67128,24125,21912,86619,40117,06522,36122,19316,58521,62336,48937,51949,49158,93452,59338,67358,635000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,000
6,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32
0
32
0
47
0
59
0
67
0
69
0
80
0
0
0
0
0
0
0
0
0
1,225
-65
-65
-65
1,606
-65
-65
0
0-65-651,606-65-65-651,225000000000800690670590470320320000000000000000006,0006,0000000000000000000000000
       Net Receivables 
20,736
27,976
28,478
27,414
0
40,531
39,398
44,742
44,742
46,506
46,506
42,537
42,537
58,919
58,919
0
56,079
0
60,317
60,113
63,443
65,573
71,203
72,912
58,017
58,633
57,037
60,518
62,400
66,999
57,988
64,024
63,337
57,905
66,572
66,361
63,754
58,693
59,584
52,236
59,014
52,557
56,664
61,422
54,036
50,453
50,330
56,268
58,799
62,343
62,200
62,456
70,218
72,738
89,895
87,362
78,386
93,895
82,046
94,336
110,624
109,596
150,172
169,159
121,426
150,182
180,011
161,318
126,379
139,133
143,314
131,488
131,488143,314139,133126,379161,318180,011150,182121,426169,159150,172109,596110,62494,33682,04693,89578,38687,36289,89572,73870,21862,45662,20062,34358,79956,26850,33050,45354,03661,42256,66452,55759,01452,23659,58458,69363,75466,36166,57257,90563,33764,02457,98866,99962,40060,51857,03758,63358,01772,91271,20365,57363,44360,11360,317056,079058,91958,91942,53742,53746,50646,50644,74244,74239,39840,531027,41428,47827,97620,736
       Other Current Assets 
194
60
888
2,230
0
308
0
0
0
0
0
0
0
0
0
0
0
0
61,472
25,000
11,000
65,573
72,380
72,912
59,662
58,633
58,232
60,518
63,622
66,999
59,335
64,024
64,560
57,905
67,795
66,361
65,144
58,693
60,973
52,236
60,403
52,557
58,308
61,422
55,395
50,453
51,975
56,268
60,185
63,852
63,632
65,911
78,601
79,662
91,648
87,608
80,203
93,928
84,217
95,031
114,288
813
161,854
173,068
142,938
3,867
6,173
1,748
4,768
5,874
4,520
0
04,5205,8744,7681,7486,1733,867142,938173,068161,854813114,28895,03184,21793,92880,20387,60891,64879,66278,60165,91163,63263,85260,18556,26851,97550,45355,39561,42258,30852,55760,40352,23660,97358,69365,14466,36167,79557,90564,56064,02459,33566,99963,62260,51858,23258,63359,66272,91272,38065,57311,00025,00061,47200000000000030802,23088860194
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50,956
50,995
52,975
53,584
58,891
58,280
73,917
84,809
91,321
90,797
86,806
91,639
98,440
98,295
91,794
95,706
99,287
98,436
103,848
104,741
109,764
111,517
111,734
112,436
120,776
120,826
120,110
121,180
130,215
130,302
130,674
132,277
148,696
182,137
182,257
182,637
193,326
191,765
192,365
194,858
209,861
205,240
204,948
208,564
226,314
222,901
224,631
228,846
255,630
253,609
261,867
263,662
290,553
293,248
293,248290,553263,662261,867253,609255,630228,846224,631222,901226,314208,564204,948205,240209,861194,858192,365191,765193,326182,637182,257182,137148,696132,277130,674130,302130,215121,180120,110120,826120,776112,436111,734111,517109,764104,741103,84898,43699,28795,70691,79498,29598,44091,63986,80690,79791,32184,80973,91758,28058,89153,58452,97550,99550,956000000000000000000
       Property Plant Equipment 
3,208
5,549
11,332
14,034
0
17,863
21,577
26,401
26,401
29,817
29,817
31,290
31,290
32,539
32,539
0
40,975
0
42,659
42,644
42,842
43,077
45,857
46,580
47,411
49,394
53,791
53,724
54,725
56,098
60,199
59,840
62,235
65,138
73,593
72,496
77,227
77,864
81,803
80,725
80,400
80,813
82,822
81,370
81,089
81,724
89,056
89,129
89,095
90,592
95,837
117,283
121,064
122,988
131,608
130,755
131,293
136,862
155,395
154,962
159,426
165,191
181,775
179,126
182,648
187,474
215,541
215,463
223,785
226,655
253,652
256,616
256,616253,652226,655223,785215,463215,541187,474182,648179,126181,775165,191159,426154,962155,395136,862131,293130,755131,608122,988121,064117,28395,83790,59289,09589,12989,05681,72481,08981,37082,82280,81380,40080,72581,80377,86477,22772,49673,59365,13862,23559,84060,19956,09854,72553,72453,79149,39447,41146,58045,85743,07742,84242,64442,659040,975032,53932,53931,29031,29029,81729,81726,40126,40121,57717,863014,03411,3325,5493,208
       Goodwill 
0
1,441
1,441
1,441
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000000001,4411,4411,4410
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,641
2,544
2,351
2,348
2,123
2,108
2,098
2,080
2,108
2,147
2,098
1,972
1,914
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001,9141,9722,0982,1472,1082,0802,0982,1082,1232,3482,3512,5442,641000000000000000000000000000000000000000000
       Intangible Assets 
1,191
1,449
1,460
1,469
0
731
749
762
762
745
745
743
743
974
974
0
1,275
0
2,290
2,320
2,686
2,668
2,736
2,754
2,892
2,937
3,176
3,155
5,779
8,702
14,468
14,393
14,742
15,239
17,206
17,287
17,567
17,812
18,881
18,551
18,665
18,603
24,872
26,459
25,829
25,212
27,078
26,589
26,233
25,993
34,650
47,395
47,012
46,130
45,079
0
43,151
0
41,413
40,522
39,690
38,887
38,558
0
36,901
0
35,744
0
34,249
0
33,902
0
033,902034,249035,744036,901038,55838,88739,69040,52241,413043,151045,07946,13047,01247,39534,65025,99326,23326,58927,07825,21225,82926,45924,87218,60318,66518,55118,88117,81217,56717,28717,20615,23914,74214,39314,4688,7025,7793,1553,1762,9372,8922,7542,7362,6682,6862,3202,29001,275097497474374374574576276274973101,4691,4601,4491,191
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,086
2,100
322
324
6,325
6,132
132
26,531
28,281
27,374
134
19,287
16,256
16,256
6,683
6,811
208
208
209
209
209
2,759
2,860
2,917
2,830
2,659
2,466
2,463
2,188
2,173
2,163
2,145
2,173
2,212
2,163
2,037
1,979
2,011
1,956
1,945
1,948
1,996
2,079
2,143
2,131
2,211
1,290
2,184
2,267
2,278
1,671
2,781
656
901
9016562,7811,6712,2782,2672,1841,2902,2112,1312,1432,0791,9961,9481,9451,9562,0111,9792,0372,1632,2122,1732,1452,1632,1732,1882,4632,4662,6592,8302,9172,8602,7592092092092082086,8116,68316,25616,25619,28713427,37428,28126,5311326,1326,3253243222,1002,086000000000000000000
> Total Liabilities 
30,797
40,038
44,308
62,126
0
65,360
60,235
52,722
52,722
67,190
67,190
75,156
75,156
77,582
77,582
0
109,681
0
108,753
107,569
109,640
106,855
114,087
100,158
99,021
93,346
95,916
92,513
95,983
95,867
91,459
86,623
96,483
90,837
102,850
96,742
105,326
99,864
99,062
91,419
103,095
92,311
104,442
111,921
112,882
98,190
106,695
108,694
119,133
115,057
115,228
133,213
149,814
138,367
188,825
190,347
191,587
192,257
200,739
194,038
240,383
232,034
261,700
319,160
391,215
329,182
357,324
316,399
380,047
276,087
256,390
254,881
254,881256,390276,087380,047316,399357,324329,182391,215319,160261,700232,034240,383194,038200,739192,257191,587190,347188,825138,367149,814133,213115,228115,057119,133108,694106,69598,190112,882111,921104,44292,311103,09591,41999,06299,864105,32696,742102,85090,83796,48386,62391,45995,86795,98392,51395,91693,34699,021100,158114,087106,855109,640107,569108,7530109,681077,58277,58275,15675,15667,19067,19052,72252,72260,23565,360062,12644,30840,03830,797
   > Total Current Liabilities 
24,127
26,068
31,904
40,249
0
40,123
34,520
27,221
27,221
35,413
35,413
41,755
41,755
38,719
38,719
0
55,035
0
51,627
48,303
51,956
49,246
56,756
52,281
56,862
52,144
55,132
52,507
61,467
62,215
58,340
54,082
63,821
46,822
62,117
57,164
68,146
56,092
59,226
53,856
68,526
60,447
76,442
66,686
69,857
58,717
73,223
80,186
91,191
85,839
87,512
89,398
104,913
95,036
106,709
108,534
111,556
111,815
122,889
118,342
167,373
159,434
190,388
248,705
320,569
258,337
293,887
255,405
321,594
220,774
199,843
191,246
191,246199,843220,774321,594255,405293,887258,337320,569248,705190,388159,434167,373118,342122,889111,815111,556108,534106,70995,036104,91389,39887,51285,83991,19180,18673,22358,71769,85766,68676,44260,44768,52653,85659,22656,09268,14657,16462,11746,82263,82154,08258,34062,21561,46752,50755,13252,14456,86252,28156,75649,24651,95648,30351,627055,035038,71938,71941,75541,75535,41335,41327,22127,22134,52040,123040,24931,90426,06824,127
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,545
1,959
8,120
1,983
8,780
9,255
9,339
8,406
8,625
8,400
8,718
4,286
4,409
4,274
4,949
5,843
8,241
10,147
11,479
12,671
13,353
12,966
13,001
13,024
14,303
16,208
18,135
19,069
18,878
17,635
17,453
14,614
10,883
12,572
5,441
5,768
6,003
5,097
5,335
5,584
5,214
6,400
6,225
6,751
6,814
12,697
12,427
11,960
11,580
13,185
22,146
22,14613,18511,58011,96012,42712,6976,8146,7516,2256,4005,2145,5845,3355,0976,0035,7685,44112,57210,88314,61417,45317,63518,87819,06918,13516,20814,30313,02413,00112,96613,35312,67111,47910,1478,2415,8434,9494,2744,4094,2868,7188,4008,6258,4069,3399,2558,7801,9838,1201,9598,545000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,794
51,300
49,135
14,303
16,208
18,135
19,069
18,878
17,635
17,453
14,614
7,283
9,112
0
0
0
2,028
0
0
0
2,959
0
2,788
0
8,238
0
0
0
8,060
0
08,0600008,23802,78802,9590002,0280009,1127,28314,61417,45317,63518,87819,06918,13516,20814,30349,13551,30033,794000000000000000000000000000000000000000000
       Accounts payable 
16,730
12,136
18,119
22,469
0
24,246
23,042
18,598
18,598
23,643
23,643
32,399
32,399
24,877
24,877
0
23,329
0
46,053
42,204
8,578
34,589
51,209
38,313
27,235
37,352
32,005
37,141
46,691
46,887
34,421
39,250
34,714
39,665
46,601
49,275
35,113
44,640
36,982
39,080
37,057
44,011
50,221
49,926
35,698
40,017
42,129
57,881
50,970
63,413
47,875
70,125
89,402
80,166
68,770
100,487
85,805
86,544
63,452
81,178
71,516
101,430
97,407
133,376
97,564
126,237
128,484
135,331
107,934
113,637
107,593
106,639
106,639107,593113,637107,934135,331128,484126,23797,564133,37697,407101,43071,51681,17863,45286,54485,805100,48768,77080,16689,40270,12547,87563,41350,97057,88142,12940,01735,69849,92650,22144,01137,05739,08036,98244,64035,11349,27546,60139,66534,71439,25034,42146,88746,69137,14132,00537,35227,23538,31351,20934,5898,57842,20446,053023,329024,87724,87732,39932,39923,64323,64318,59818,59823,04224,246022,46918,11912,13616,730
       Other Current Liabilities 
6,626
11,523
11,607
11,055
0
12,811
8,681
4,606
4,606
6,250
6,250
2,546
2,546
8,033
8,033
0
21,091
0
5,574
6,099
43,378
4,658
4,298
5,605
4,348
43,364
13,872
6,027
4,338
6,703
4,084
6,114
24,821
2,748
11,242
2,940
27,190
3,211
12,097
3,297
18,798
3,083
13,255
3,759
21,135
4,397
14,886
4,170
21,152
3,548
22,002
1,820
897
3,987
25,367
2,606
19,983
25,268
54,340
30,732
89,359
52,790
86,581
109,104
84,953
12,188
37,805
9,021
109,380
19,263
40,021
62,461
62,46140,02119,263109,3809,02137,80512,18884,953109,10486,58152,79089,35930,73254,34025,26819,9832,60625,3673,9878971,82022,0023,54821,1524,17014,8864,39721,1353,75913,2553,08318,7983,29712,0973,21127,1902,94011,2422,74824,8216,1144,0846,7034,3386,02713,87243,3644,3485,6054,2984,65843,3786,0995,574021,09108,0338,0332,5462,5466,2506,2504,6064,6068,68112,811011,05511,60711,5236,626
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
57,126
59,266
57,684
57,609
57,331
47,877
42,159
41,202
40,784
40,006
34,516
33,652
33,119
32,541
32,662
44,015
40,733
39,578
37,180
43,772
39,836
37,563
34,569
31,864
28,000
45,235
43,025
39,473
33,472
28,508
27,942
29,218
27,716
43,815
44,901
43,331
82,116
81,813
80,031
80,442
77,850
75,696
73,010
72,600
71,312
70,455
70,646
70,845
63,437
60,994
58,453
55,313
56,547
63,635
63,63556,54755,31358,45360,99463,43770,84570,64670,45571,31272,60073,01075,69677,85080,44280,03181,81382,11643,33144,90143,81527,71629,21827,94228,50833,47239,47343,02545,23528,00031,86434,56937,56339,83643,77237,18039,57840,73344,01532,66232,54133,11933,65234,51640,00640,78441,20242,15947,87757,33157,60957,68459,26657,126000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66,378
0
59,441
0
54,540
0
0
0
00054,540059,441066,3780000000000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-8,545
-1,959
-8,120
-1,983
-8,780
-9,255
-9,339
-8,406
-8,625
-8,400
-8,718
-4,286
-4,409
-4,274
-4,949
-5,843
-8,241
-10,147
-11,479
-12,671
-13,353
-12,966
-13,001
-13,024
-14,303
-16,208
-18,135
-19,069
-18,878
-17,635
-17,453
4,495
-10,883
8,299
-5,441
-5,768
-6,003
12,449
-5,335
-5,584
-5,214
11,263
-6,225
10,817
-6,814
5,159
-12,427
-11,960
-11,580
5,607
-22,146
-22,1465,607-11,580-11,960-12,4275,159-6,81410,817-6,22511,263-5,214-5,584-5,33512,449-6,003-5,768-5,4418,299-10,8834,495-17,453-17,635-18,878-19,069-18,135-16,208-14,303-13,024-13,001-12,966-13,353-12,671-11,479-10,147-8,241-5,843-4,949-4,274-4,409-4,286-8,718-8,400-8,625-8,406-9,339-9,255-8,780-1,983-8,120-1,959-8,545000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,240
0
6,113
0
8,429
0
8,386
0
8,371
0
8,150
0
7,929
0
7,708
0
7,487
0
7,266
0
7,045
0
6,824
0
6,603
0
0
0
0
0
000006,60306,82407,04507,26607,48707,70807,92908,15008,37108,38608,42906,11304,240000000000000000000000000000000000000000000
> Total Stockholder Equity
17,805
40,914
45,283
41,351
25,810
50,375
51,924
63,162
63,162
68,715
68,715
70,247
70,247
87,205
87,205
87,205
98,578
0
104,134
108,943
108,272
111,452
113,981
119,108
120,246
123,574
126,447
132,479
133,393
140,222
144,464
149,968
151,157
154,492
158,470
165,138
159,270
162,225
164,785
173,982
175,500
179,013
183,406
190,021
190,122
191,436
191,687
198,625
193,114
201,101
287,472
294,452
299,307
313,807
322,386
336,313
352,243
369,457
373,700
397,344
403,862
453,032
470,976
425,553
399,022
441,921
520,012
567,259
516,643
551,501
539,387
519,677
519,677539,387551,501516,643567,259520,012441,921399,022425,553470,976453,032403,862397,344373,700369,457352,243336,313322,386313,807299,307294,452287,472201,101193,114198,625191,687191,436190,122190,021183,406179,013175,500173,982164,785162,225159,270165,138158,470154,492151,157149,968144,464140,222133,393132,479126,447123,574120,246119,108113,981111,452108,272108,943104,134098,57887,20587,20587,20570,24770,24768,71568,71563,16263,16251,92450,37525,81041,35145,28340,91417,805
   Common Stock
214
10,674
9,936
3,454
0
147
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
0
3,000
0
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,241
3,241
3,241
3,241
3,241
3,241
3,241
3,2413,2413,2413,2413,2413,2413,2413,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,00003,00003,0003,0003,0003,0003,0003,0003,0003,0003,00014703,4549,93610,674214
   Retained Earnings 
2,035
30,233
34,351
37,704
0
50,174
48,861
60,048
60,048
68,478
68,478
71,045
71,045
85,482
85,482
0
97,405
0
102,496
107,348
12,874
109,674
112,047
5,257
12,959
16,632
125,206
130,664
132,325
137,506
141,965
147,895
148,923
153,846
157,685
164,211
162,893
165,982
169,299
178,721
180,389
184,005
188,510
194,934
194,845
196,243
196,496
203,411
198,117
206,202
204,687
211,823
216,820
231,742
241,057
256,392
273,448
293,516
302,215
329,550
338,711
390,754
445,426
498,453
472,475
384,351
456,031
502,010
451,719
504,667
555,534
570,492
570,492555,534504,667451,719502,010456,031384,351472,475498,453445,426390,754338,711329,550302,215293,516273,448256,392241,057231,742216,820211,823204,687206,202198,117203,411196,496196,243194,845194,934188,510184,005180,389178,721169,299165,982162,893164,211157,685153,846148,923147,895141,965137,506132,325130,664125,20616,63212,9595,257112,047109,67412,874107,348102,496097,405085,48285,48271,04571,04568,47868,47860,04860,04848,86150,174037,70434,35130,2332,035
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
87,636
0
87,636
0
0
87,636
0
87,636
0
87,636
0
0
0
00087,636087,636087,6360087,636087,63600000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000-28,7200-23,876000000000-8,698-8,600-8,383-8,407-8,405-8,321-8,511-8,701-8,589-8,486-8,336-8,112-7,355-7,221-2,672-2,813-2,739-1,061-1,208-782-585-2,267-1,540-2,060-2,148-2,077-1,880-1,922-1,938-2,064-2,003-1,9600-1,8250-1,198-1,198-4,087-4,087-2,602-2,602000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,362
-1,405
92,398
-1,222
-1,066
110,851
104,287
103,942
-1,759
-1,185
-1,932
-284
-501
-927
-766
-2,354
-2,215
-2,073
-6,623
-6,757
-7,514
-7,739
-7,889
-7,992
-8,104
-7,913
-7,723
-7,807
-7,809
-7,786
-8,003
-8,101
79,421
79,265
79,123
78,701
77,965
76,557
75,431
72,577
68,121
64,430
61,787
-2
22,186
-76,264
-77,484
53,662
60,075
61,346
61,034
42,924
-20,040
-54,056
-54,056-20,04042,92461,03461,34660,07553,662-77,484-76,26422,186-261,78764,43068,12172,57775,43176,55777,96578,70179,12379,26579,421-8,101-8,003-7,786-7,809-7,807-7,723-7,913-8,104-7,992-7,889-7,739-7,514-6,757-6,623-2,073-2,215-2,354-766-927-501-284-1,932-1,185-1,759103,942104,287110,851-1,066-1,22292,398-1,405-1,362000000000000000000



Balance Sheet

Currency in EUR. All numbers in thousands.